|
186 Products |
| 186 Products |
|
1696 Diseases |  |
94663 News |  |
| «12...1052105310541055105610571058105910601061106210631064» |
- || Emestop (ramosetron hydrochloride) / Samyang Group
New P3 trial: Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone (clinicaltrials.gov) - Feb 20, 2012
P3, N=338, Recruiting, Sponsor: Hallym University Medical Center
- ||||| Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
New P2 trial: LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris (clinicaltrials.gov) - Feb 20, 2012
P2, N=376, Completed, Sponsor: LEO Pharma
- |||| evofosfamide (TH 302) / Molecular Templates, ImmunoGenesis
Clinical: Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 20, 2012
P1/2, N=60, Recruiting, Sponsor: Threshold Pharmaceuticals
Not yet recruiting --> Recruiting
- Pulmicort Turbuhaler (budesonide dry-powder inhaler) / AstraZeneca
Enrollment open: Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth (clinicaltrials.gov) - Feb 19, 2012
P4, N=60, Recruiting, Sponsor: West Penn Allegheny Health System
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||||| budesonide ER / Generic mfg.
Trial completion: (CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis. (clinicaltrials.gov) - Feb 16, 2012
P3, N=123, Completed, Sponsor: Salix Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Henletor (torsemide) / Orchid
Enrollment change: The Effects of Glucocorticoids on Mortality and Renal Function in Patients With Acute Decompensated Heart Failure (clinicaltrials.gov) - Feb 16, 2012
P2/3, N=102, Completed, Sponsor: Hebei Medical University
Active, not recruiting --> Completed N=200 --> 102
- bortezomib / Generic mfg., dexamethasone / Generic mfg.
Enrollment closed: Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT (clinicaltrials.gov) - Feb 16, 2012
P2/3, N=40, Active, not recruiting, Sponsor: Tampere University Hospital
N=200 --> 102 Recruiting --> Active, not recruiting
- | Henletor (torsemide) / Orchid
Trial completion: The Effects of Glucocorticoids on Mortality and Renal Function in Patients With Acute Decompensated Heart Failure (clinicaltrials.gov) - Feb 16, 2012
P2/3, N=102, Completed, Sponsor: Hebei Medical University
Recruiting --> Active, not recruiting Recruiting --> Completed
- Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
New P1 trial, Combination therapy: Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial (clinicaltrials.gov) - Feb 15, 2012
P1, N=10, Recruiting, Sponsor: Celltrion
- | Emestop (ramosetron hydrochloride) / Samyang Group
Enrollment closed: Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer (clinicaltrials.gov) - Feb 15, 2012
P2, N=41, Active, not recruiting, Sponsor: Hallym University Medical Center
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center, Nasonex (mometasone furoate nasal spray) / Merck (MSD)
Enrollment change: Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis (clinicaltrials.gov) - Feb 14, 2012
P3, N=185, Completed, Sponsor: Sunovion
Recruiting --> Active, not recruiting N=126 --> 185
- | Beclazone (beclometasone hydrofluoroalkane inhaler) / Teva
New P1 trial: Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol (clinicaltrials.gov) - Feb 14, 2012
P1, N=30, Completed, Sponsor: Teva Pharmaceutical Industries
- dexamethasone injection / Generic mfg.
New P1 trial: Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients (clinicaltrials.gov) - Feb 14, 2012
P1, N=50, Completed, Sponsor: Xiao-Ming Mao
- ||||| Korlym (mifepristone) / Corcept Therap
Enrollment change: A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression (clinicaltrials.gov) - Feb 13, 2012
P3, N=87, Completed, Sponsor: Corcept Therapeutics
N=126 --> 185 N=110 --> 87
- || budesonide ER / Generic mfg.
New P3 trial: Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX (clinicaltrials.gov) - Feb 12, 2012
P3, N=509, Completed, Sponsor: Salix Pharmaceuticals
- |||||| budesonide / Generic mfg.
Enrollment open: Safety Study of Entocort for Children With Crohn's Disease (clinicaltrials.gov) - Feb 9, 2012
P3, N=126, Recruiting, Sponsor: AstraZeneca
N=110 --> 87 Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Combination therapy: Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus (clinicaltrials.gov) - Feb 9, 2012
P2, N=20, Completed, Sponsor: Chinese University of Hong Kong
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- fludrocortisone / Generic mfg., hydrocortisone / Generic mfg.
Trial withdrawal: Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis (clinicaltrials.gov) - Feb 9, 2012
P4, N=0, Withdrawn, Sponsor: CAMC Health System
Active, not recruiting --> Completed Terminated --> Withdrawn
- | Sylvant (siltuximab) / Jazz
New P1/2 trial: Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) (clinicaltrials.gov) - Feb 9, 2012
P1/2, N=11, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||| budesonide ER / Generic mfg.
Enrollment change: (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets (clinicaltrials.gov) - Feb 8, 2012
P3, N=61, Completed, Sponsor: Salix Pharmaceuticals
Terminated --> Withdrawn N=80 --> 61
- ||||||| budesonide ER / Generic mfg.
Trial completion: (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets (clinicaltrials.gov) - Feb 8, 2012
P3, N=61, Completed, Sponsor: Salix Pharmaceuticals
N=80 --> 61 Enrolling by invitation --> Completed
- ||||||| Asacol foam (mesalazine rectal foam) / Nogra Pharma
Trial completion: (CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis (clinicaltrials.gov) - Feb 8, 2012
P3, N=510, Completed, Sponsor: Salix Pharmaceuticals
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- ||||||| budesonide ER / Generic mfg.
Trial completion: (CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis (clinicaltrials.gov) - Feb 8, 2012
P3, N=514, Completed, Sponsor: Salix Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment change: Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis (clinicaltrials.gov) - Feb 8, 2012
P2, N=21, Completed, Sponsor: IRCCS Policlinico S. Matteo
Active, not recruiting --> Completed N=34 --> 21
- ||||||| Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
Trial completion: Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Feb 8, 2012
P3, N=512, Completed, Sponsor: GlaxoSmithKline
N=34 --> 21 Active, not recruiting --> Completed
- | Trial completion: Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis (clinicaltrials.gov) - Feb 8, 2012
P2, N=21, Completed, Sponsor: IRCCS Policlinico S. Matteo
Active, not recruiting --> Completed Recruiting --> Completed
- dexamethasone / Generic mfg.
Trial completion: A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Branch Retinal Vein Occlusion (clinicaltrials.gov) - Feb 8, 2012
P1/2, N=0, Completed, Sponsor: Sanwa Kagaku Kenkyusho Co., Ltd.
Recruiting --> Completed Active, not recruiting --> Completed
- montelukast / Generic mfg.
Trial initiation date: Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma (clinicaltrials.gov) - Feb 7, 2012
P4, N=99, Recruiting, Sponsor: The First Affiliated Hospital of Guangzhou Medical University
Active, not recruiting --> Completed Initiation date: Oct 2011 --> Feb 2012
- |||| budesonide/formoterol / Generic mfg.
Trial completion: CHASE 2: A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy (clinicaltrials.gov) - Feb 6, 2012
P2, N=54, Completed, Sponsor: AstraZeneca
Initiation date: Oct 2011 --> Feb 2012 Recruiting --> Completed
- methylprednisolone acetate / Generic mfg.
Clinical: Epidural Study of Patients With Chronic Lower Back Pain (clinicaltrials.gov) - Feb 6, 2012
P=N/A, N=252, Completed, Sponsor: Hamilton Health Sciences Corporation
Recruiting --> Completed Recruiting --> Completed
- Sylvant (siltuximab) / Jazz
Enrollment change, Combination therapy: A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 6, 2012
P3, N=0, Withdrawn, Sponsor: Centocor, Inc.
Recruiting --> Completed N=500 --> 0
- |||||||||| betamethasone/dexchlorpheniramine maleate / Generic mfg., prednisolone / Generic mfg.
New P3 trial: Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Cutaneous Rash Treatment (clinicaltrials.gov) - Feb 6, 2012
P3, N=140, Not yet recruiting, Sponsor: EMS
- |||||||||| betamethasone/dexchlorpheniramine maleate / Generic mfg., prednisolone / Generic mfg.
New P3 trial: Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Persistent Allergic Rhinitis Treatment (clinicaltrials.gov) - Feb 6, 2012
P3, N=210, Not yet recruiting, Sponsor: EMS
- |||| Vizimpro (dacomitinib) / Pfizer
Enrollment open, Adverse events, Patient reported outcomes, Metastases: ARCHER 1042: Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO (clinicaltrials.gov) - Feb 4, 2012
P2, N=184, Recruiting, Sponsor: Pfizer
N=500 --> 0 Not yet recruiting --> Recruiting
- bortezomib / Generic mfg., pegylated liposomal doxorubicin / Generic mfg.
Trial completion, Combination therapy: Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma (clinicaltrials.gov) - Feb 4, 2012
P=N/A, N=30, Completed, Sponsor: University of Michigan Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion: UMCC 2004.047: Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma (clinicaltrials.gov) - Feb 4, 2012
P2, N=40, Completed, Sponsor: University of Michigan Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Arzerra (ofatumumab) / Novartis, Genmab
New P2 trial, Combination therapy: NCI-2011-03562: Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Feb 2, 2012
P2, N=53, Recruiting, Sponsor: Roswell Park Cancer Institute
- |||| Empliciti (elotuzumab) / AbbVie, BMS
Enrollment open: Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 2, 2012
P2, N=150, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Trial completion: Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF) (clinicaltrials.gov) - Feb 1, 2012
P=N/A, N=227, Completed, Sponsor: Orion Corporation, Orion Pharma
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Trial completion: Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis (clinicaltrials.gov) - Feb 1, 2012
P3, N=80, Completed, Sponsor: Sunovion
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Veramyst (fluticasone furoate nasal spray) / GSK
Trial completion: Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents (clinicaltrials.gov) - Feb 1, 2012
P3, N=350, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Empliciti (elotuzumab) / AbbVie, BMS
Enrollment closed, Combination therapy: Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone (clinicaltrials.gov) - Feb 1, 2012
P1, N=20, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Bufomix Easyhaler (budesonide/formoterol dry powder inhaler) / Orion Corp
Trial completion: Pharmacokinetic Pilot Study on Budesonide/Formoterol (clinicaltrials.gov) - Feb 1, 2012
P=N/A, N=17, Completed, Sponsor: Orion Corporation, Orion Pharma
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| Rituxan (rituximab) / Roche
Combination therapy: Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 1, 2012
P2, N=54, Completed, Sponsor: Biogen Idec
Recruiting --> Completed Active, not recruiting --> Completed
- dexamethasone / Generic mfg.
Enrollment change: Using Dexamethasone After Uvulopalatopharyngoplasty (clinicaltrials.gov) - Jan 31, 2012
P1, N=15, Completed, Sponsor: University of Oklahoma
Active, not recruiting --> Completed N=40 --> 15
- dexamethasone / Generic mfg.
Trial completion: Using Dexamethasone After Uvulopalatopharyngoplasty (clinicaltrials.gov) - Jan 31, 2012
P1, N=15, Completed, Sponsor: University of Oklahoma
N=40 --> 15 Recruiting --> Completed
- methylprednisolone sodium succinate / Generic mfg.
New P2/3 trial: Optic Neuritis Recovery After Oral or IV Corticosteroids (clinicaltrials.gov) - Jan 30, 2012
P2/3, N=46, Recruiting, Sponsor: London Health Sciences Centre
- Signifor LAR (pasireotide long acting release) / Recordati
Trial withdrawal, Combination therapy: SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma (clinicaltrials.gov) - Jan 30, 2012
P2, N=0, Withdrawn, Sponsor: University of Pittsburgh
Recruiting --> Completed Not yet recruiting --> Withdrawn
- Signifor LAR (pasireotide long acting release) / Recordati
Enrollment change, Combination therapy: SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma (clinicaltrials.gov) - Jan 30, 2012
P2, N=0, Withdrawn, Sponsor: University of Pittsburgh
Not yet recruiting --> Withdrawn N=40 --> 0
- cyclophosphamide / Generic mfg., docetaxel / Generic mfg.
Biomarker, Metastases: Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses (clinicaltrials.gov) - Jan 30, 2012
P2, N=41, Recruiting, Sponsor: National Cancer Centre, Singapore